Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study.
A comparison has been made of the relapse rates between 7 and 30 months for four 6-month regimens. Streptomycin plus isoniazid plus rifampicin had a relapse rate of 2 per cent of 171 patients; isoniazid plus rifampicin had a relapse rate of 7 per cent of 164. An initial 2 months of streptomycin, isoniazid, rifampicin, and pyrazinamide, when followed by thiacetazone plus isoniazid, had a relapse rate of 7 per cent of 179, and when followed by streptomycin plus isoniazid plus pyrazinamide twice a week the relapse rate was 4 per cent of 159 patients. Of the 36 relapses, 32 occurred in the first 6 months after stopping chemotherapy and 35 were with drug-susceptible organisms. The difference between the relapse rate on the streptomycin plus isoniazid plus rifampicin regimen and the isoniazid plus rifampicin and thiacetazone plus isoniazid regimens approached significance (P =0.06 for both comparisons).
D000293:Adolescent; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000031:analogs & derivatives / Q000627:therapeutic use* / Q000652:urine; D011718:Pyrazinamide / Q000627:therapeutic use*; D012294:Rifamycins / Q000627:therapeutic use*; D013307:Streptomycin / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D012294:Rifamycins; D011718:Pyrazinamide; D007538:Isoniazid; D013307:Streptomycin